Sensorium Therapeutics

In the U.S., an estimated $24.5 billion is spent annually to treat #epilepsy and #seizures. New treatment options are needed to overcome this debilitating disease, and that’s why we remain committed to discovering new therapies for people awaiting innovation. One way our team does this is by leveraging the power of #AI to more quickly identify and develop new chemical compounds to treat complex neurological disorders, including epilepsy. Visit sensorium.bio to learn about our approach. To join the cause, visit epilepsy.com. #AIinMedicine #DrugDiscovery #EpilepsyAwarenessMonth #Biotech

For a third of patients with #epilepsy, #anxiety is an all-too-common feeling. As we continue celebrating Epilepsy Awareness Month and the millions of people affected globally, our team remains committed to discovering novel solutions. Our second clinical program, SENS-03, has shown efficacy in multiple validated seizure models and preclinical anxiety models and aims to tackle both seizures and co-morbid anxiety. To help raise awareness, Sensorium and SmartLabs are proudly hosting a clothing drive to benefit the Epilepsy Foundation New England. To learn more and join the cause visit epilepsy.com. Discover how we’re working to revolutionize drug discovery for diseases like epilepsy at sensorium.bio. #EpilepsyAwareness #NEAM2024 #ShareYourPurplePower #Biotech

DYK? Epilepsy affects over 50 million people worldwide, with 30-40% of patients continuing to have seizures despite available treatments. This Epilepsy Awareness Month, we’re sounding the alarm on the need for big ideas and new approaches to bring new hope to people living with #epilepsy. All month long, Sensorium and SmartLabs are hosting a clothing drive to benefit the Epilepsy Foundation New England, and we welcome anyone local to Boston to contact us for details on how to donate. To learn more and join the cause, visit epilepsy.com. Discover how we’re working to revolutionize drug discovery for diseases like epilepsy at sensorium.bio. #EpilepsyAwareness #NEAM2024 and #ShareYourPurplePower #Biotech

Big thinkers unite! Aaron Van Hooser, PhD, Senior Director of Computational Biology, will be in Boston at Discovery & Development by Oxford Global US 2024 this week speaking about how we’re leveraging #GenerativeAI to develop nature-inspired medicines for #CNS. Sensorium is revolutionizing drug discovery by fusing AI with ethnobotanical wisdom, leveraging the world's largest integrated ethnobotanical database to uncover natural compounds with unprecedented potential for addressing human diseases through novel mechanisms and clinically relevant endpoints. Get the details and register: https://lnkd.in/dijNAsfD #AIinDrugDiscovery #DiscoveryUS #Biotech

?? Excited to share that Aaron Van Hooser, PhD, our Senior Director of Computational Biology, is heading to the Garden State later this month to discuss using #GenerativeAI to develop nature-inspired medicines at the 21st BioPharma Drug Discovery Nexus. At Sensorium, we are working to transform drug discovery by integrating #AI with ethnobotanical insights, and we have created the largest and most integrated ethnobotanical and ethnopharmacological database. Our innovative AI product engine identifies natural compounds with groundbreaking potential, revealing novel mechanisms and clinically relevant endpoints to address human diseases. Learn more and register to join us in New Jersey: https://lnkd.in/dQFaspav #AIinDrugDiscovery #BioPharmaNexus #Biotech

?? We were proud to contribute to the buzz in Chicago this week at the Society for Neuroscience #SfN24! The team presented new preclinical data on our lead assets—SENS-01, a novel fast-acting anxiolytic for #anxiety disorders, and SENS-03, a new treatment for drug-resistant #epilepsy—as well as updates on our differentiated drug discovery strategy. As we gear up to enter the clinic in early 2025, we’re committed to advancing first-in-class #CNS medicines to address critical unmet need. See the key takeaways and read the release: https://lnkd.in/egfSazEs #Neuroscience2024 #DrugDiscovery #Data #Biotech

This weekend we’re heading to the Society for Neuroscience #SfN24 to share new data on lead assets SENS-01 for anxiety and SENS-03 for epilepsy and highlight advancements in our innovative drug discovery strategy. We look forward to engaging with leading researchers and science in the space as we prepare to enter the clinic early next year. ?? Register and learn more about the world’s largest neuroscience conference here: https://lnkd.in/d53mNcsW ?? Stop by our poster sessions to learn more about our work to bring forward best-in-class, novel therapies for #CNS diseases. We hope to see you in Chicago! #Neuroscience2024 #DrugDiscovery #Anxiety #Epilepsy #Biotech

We are pleased to welcome Sam Rasty, PhD, MBA to the Sensorium team as our Chief Business Officer! Sam brings over 25 years of of R&D, strategy, commercial, BD&L, and corporate leadership experience in key leadership roles across #biotech and #pharma. ? He joins Sensorium at an important time as we prepare to become a clinical stage company in 2025. ? ? Read more here: https://lnkd.in/eJnrp7Gc

This week our CSO?Jeffrey Brown?will be attending the American Academy of Neurology Annual Meeting. At the Meeting he will be sharing more about Sensorium’s SENS-03 (epilepsy-focused) program. Please reach out if you will be attending the meeting and would like to connect!

We are excited to welcome Simba Gill to the Sensorium team as an Independent Director! Simba brings decades of leadership experience in key leadership roles across #biotech and #pharma.? He joins Sensorium at an important time as we announce our first Development Candidate Nomination of SENS-01, developed as a rapid-acting and well-tolerated therapeutic for patients with #anxiety. Read more here: https://lnkd.in/eHT_NAau